Apogee Therapeutics, Inc.

NASDAQ: APGE · Healthcare · Biotechnology

PublicHQ Waltham, MA · MiddlesexCIK 0001974640Reports USD

#1 of 1,417 Healthcare companies by revenue

EA Score

——

FH 68DQ —GM —SS 59

v0.1 · 35/100 weight · pillars only

↑ balance-sheet leverage, Altman-Z · ↓ listing tenure, Piotroski F

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$255.8M

Employees

261

as of 2026-08-06

Market cap

$8.3B

as of 2026-08-06

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$255.8M-$255.8M2025

Operating income-$285.6M-$285.6M2025

Total assets$937.1M$937.1M2025

Liabilities$33.3M$33.3M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Apogee Therapeutics, Inc.’s financial profile?

Apogee Therapeutics, Inc. earned -$255.8M in FY2025 net income.

Peers · Healthcare

ContraFect Corp.——Heart Tronics, Inc.——Nuvalent, Inc.——Immunovant, Inc.——Vaxcyte, Inc.——Belite Bio, Inc——

Neighbors

Middlesex →

GE Vernova Inc.$38.1B63C Thermo Fisher Scientific Inc.$44.6B86A Analog Devices, Inc.$11.0B87A The TJX Companies, Inc.$60.4B85A Boston Scientific Corporation$20.1B88A Symbotic Inc.$2.2B48D

Key facts

CEOMichael Thomas Henderson

SectorHealthcare

IndustryBiotechnology

HeadquartersWaltham, MA

ExchangeNASDAQ: APGE

Employees261

IPO date2023-07-14

Latest filings

8-K2026-08-11 10-Q2026-08-10 8-K2026-08-10 8-K2026-06-22 8-K2026-06-22 8-K2026-06-12 8-K2026-05-27 8-K2026-05-27

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.